[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341287-105":59,"doc-detail-341287-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","an-antibody-crisprcas-conjugate-platform-for-target-specific-delivery-and-gene-editing-in-cancer","An Antibody-CRISPR/Cas Conjugate Platform for Target-Specific Delivery and Gene Editing in Cancer","","CRISPR/Cas is a promising cancer-therapy tool, yet achieving target-specific delivery remains a key barrier to efficacy and safety. The study introduces an antibody-CRISPR/Cas conjugate platform designed for HER2-positive cancers. Cas9 is engineered by substituting specific residues with an unnatural amino acid, enabling bioorthogonal modification, complexation with a nanocarrier, and conjugation to a monoclonal HER2 antibody. The resulting antibody-conjugated CRISPR/Cas nanocomplexes selectively deliver and induce gene editing in HER2-positive cells in vitro and disrupt plk1 in vivo, suppressing tumor growth. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/an-antibody-crisprcas-conjugate-platform-for-target-specific-delivery-and-gene-editing-in-cancer/341287/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/an-antibody-crisprcas-conjugate-platform-for-target-specific-delivery-and-gene-editing-in-cancer/341287.png","ImageObject",300,407,{"name":92,"@type":93},"Violet","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What major obstacle limits CRISPR/Cas therapy for cancer in vivo?","Question",{"text":112,"@type":113},"Poor delivery and insufficient target selectivity reduce efficacy and increase side effects.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the platform achieve target-specific delivery to HER2-positive cancer?",{"text":117,"@type":113},"It conjugates an engineered CRISPR/Cas system to a monoclonal antibody targeting HER2 and complexes it with a nanocarrier for selective delivery.",{"name":119,"@type":110,"acceptedAnswer":120},"What gene is disrupted in the in vivo demonstration and what is the outcome?",{"text":121,"@type":113},"The in vivo delivery disrupts the plk1 gene in HER2-positive ovarian cancer, leading to substantial tumor growth suppression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341287,1790141765,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","RESEARCH ARTICLE  \n[www.advancedscience.com](www.advancedscience.com)  \nAn Antibody-CRISPR/Cas Conjugate Platform for Target-Speciﬁc Delivery and Gene Editing in Cancer  \nSeungju Yang, San Hae Im, Ju Yeon Chung, Juhee Lee, Kyung-Hun Lee, Yoo Kyung Kang, and Hyun Jung Chung*  \nThe CRISPR/Cas system has been introduced as an innovative tool for therapy, however achieving speciﬁc delivery to the target has been a major challenge. Here, an antibody-CRISPR/Cas conjugate platform that enables speciﬁc delivery and target gene editing in HER2-positive cancer is introduced. The CRISPR/Cas system by replacing speciﬁc residues of Cas9 with an unnatural amino acid is engineered, that can be complexed with a nanocarrier and bioorthogonally functionalized with a monoclonal antibody targeting HER2. The resultant antibody-conjugated CRISPR/Cas nanocomplexes can be speciﬁcally delivered and induce gene editing in HER2-positive cancer cells in vitro. It is demonstrated that the in vivo delivery of the antibody-CRISPR/Cas nanocomplexes can eﬀectively disrupt the plk1 gene in HER2-positive ovarian cancer, resulting in substantial suppression of tumor growth. The current study presents a useful therapeutic platform for antibody-mediated delivery of CRISPR/Cas for the treatment of various cancers and genetic diseases.  \ndisorders. [1] The disruption or correction of genes related to cell growth, survival, and resistance, can provide great advantages in cancer therapy by avoiding the need of frequent injections and preventing the chance of recurrence. [2] However, application of the CRISPR/Cas system as an in vivo therapeutic for cancer has been challenging due to the poor delivery and selectivity to the target, leading to low eﬃcacy and side eﬀects. [3] Various methods have been developed for the nonviral delivery of the CRISPR/Cas machinery, by using nanocarriers such as lipid formulations, polymers, and inorganic nanoparticles. [4] For targetspeciﬁc delivery, rationally designed lipids or ligand conjugation on nanoparticles have been reported. [5] However, the previous developments based on lipid chemistry  \n1. Introduction  \nGenome editing based on the clustered regularly interspaced short palindromic repeats/CRISPR-associated protein (CRISPR/Cas) system has been shown promising for the treatment of human diseases, such as cancers and inherited genetic  \nS. Yang, S. H. Im, J. Y. Chung, J. Lee, H. J. Chung Department of Biological Sciences  \nKorea Advanced Institute of Science and Technology Daejeon 34141, Republic of Korea  \nE-mail: [hyunjc@kaist.ac.kr](hyunjc@kaist.ac.kr)[ ](hyunjc@kaist.ac.kr)K.-H. Lee  \nDepartment of Internal Medicine Seoul National University Hospital Seoul 03080, Republic of Korea K.-H. Lee  \nCancer Research Institute Seoul National University Seoul 03080, Republic of Korea  \nY. K. Kang  \nCollege of Pharmacy Gyeongsang National University Jinju 52828, Republic of Korea  \nThe ORCID identiﬁcation number(s) for the author(s) of this article  \ncan be found under [https://doi.org/10.1002/advs.202308763](https://doi.org/10.1002/advs.202308763)[ ](https://doi.org/10.1002/advs.202308763)© 2024 The Authors. Advanced Science published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nDOI: 10.1002/advs.202308763  \nhave been mainly conﬁned to RNA therapeutics, while antibody conjugation on surfaces can aﬀect nano-formulation stability and delivery eﬃciency. [3b,c,6]  \nFor the delivery of the CRISPR/Cas ribonucleoproteins, chemical conjugation of biomolecules has been suggested as an alternative approach that can enable the desired delivery eﬀects by ﬁne-tuning the molecular properties of the cargo. [7] Particularly, the incorporation of unnatural amino acids into the CRISPR/Cas proteins can provide versatility in their modiﬁcation by bioorthogonal chemistry, enablin","cbCaiqEmMyglBzCY","https://ap.wps.com/l/cbCaiqEmMyglBzCY","pdf",9360202,12,"English","# Introduction\n## Targeted delivery challenges for CRISPR/Cas\n## Nonviral nanocarrier delivery approaches\n## Bioorthogonal engineering using unnatural amino acids\n## Study aims and platform overview","[{\"question\":\"What major obstacle limits CRISPR/Cas therapy for cancer in vivo?\",\"answer\":\"Poor delivery and insufficient target selectivity reduce efficacy and increase side effects.\"},{\"question\":\"How does the platform achieve target-specific delivery to HER2-positive cancer?\",\"answer\":\"It conjugates an engineered CRISPR/Cas system to a monoclonal antibody targeting HER2 and complexes it with a nanocarrier for selective delivery.\"},{\"question\":\"What gene is disrupted in the in vivo demonstration and what is the outcome?\",\"answer\":\"The in vivo delivery disrupts the plk1 gene in HER2-positive ovarian cancer, leading to substantial tumor growth suppression.\"}]","An Antibody-CRISPR/Cas Conjugate Platform for Target-Specific Delivery and Gene Editing in Cancer | PDF",1790041357,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd6cdb3b7ce2488650b6dba9a63244cc.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3741bd0a25efd7cc8bd8e9cad5dfa8c8.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33eb4cb34f56cd15ea18424e4053b1fb.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7c1eedbc1e13f870cc0a0329d1de9d9.webp",980,1287]